<DOC>
	<DOC>NCT00286169</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.</brief_summary>
	<brief_title>Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<criteria>Extensivedisease smallcell lung cancer Aged 70 years or older Performance status of 02 No prior chemotherapy Prior therapy for primary lesion Pneumonitis and/or pulmonary fibrosis Active concomitant malignancy</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Extensive-disease small-cell lung cancer (ED-SCLC)</keyword>
</DOC>